CUBICIN RF
Total Payments
$361,106
Transactions
639
Doctors
346
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $78.49 | 5 | 2 |
| 2019 | $614.41 | 43 | 22 |
| 2018 | $27,290 | 76 | 57 |
| 2017 | $333,124 | 515 | 299 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $350,956 | 93 | 97.2% |
| Food and Beverage | $8,151 | 545 | 2.3% |
| Space rental or facility fees (teaching hospital only) | $2,000 | 1 | 0.6% |
Payments by Type
Research
$350,956
93 transactions
General
$10,151
546 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms. | Merck Sharp & Dohme Corporation | $245,118 | 0 |
| A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Verses Active Comparator in Pediatric Subjects with Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms | Merck Sharp & Dohme Corporation | $39,601 | 0 |
| A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects Two - Seventeen Years of Age With Bacteremia caused by Staphylococcus aureus | Merck Sharp & Dohme Corporation | $28,894 | 0 |
| A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms | Merck Sharp & Dohme Corporation | $26,240 | 0 |
| Synergistic combinations to extend the spectrum of daptomycin to include resistant gram negatives | Merck Sharp & Dohme Corporation | $11,103 | 0 |
Top Doctors Receiving Payments for CUBICIN RF — Page 7
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Internal Medicine | Pasadena, CA | $17.07 | 1 |
| , M.D | Critical Care Medicine | Pasadena, CA | $17.07 | 1 |
| Funlola Famuyiwa | Internal Medicine | Reisterstown, MD | $17.07 | 1 |
| , M.D | Critical Care Medicine | Augusta, GA | $17.06 | 1 |
| , MD | Family Medicine | Augusta, GA | $17.06 | 1 |
| , M.D | Pulmonary Disease | Augusta, GA | $17.06 | 1 |
| , MD | Pulmonary Disease | Augusta, GA | $17.06 | 1 |
| , M.D | Hospitalist | Augusta, GA | $17.06 | 1 |
| , D.O | Infectious Disease | Englewood, NJ | $17.00 | 1 |
| , M.D | Infectious Disease | Miami, FL | $16.97 | 1 |
| , M.D | Internal Medicine | Omaha, NE | $16.68 | 1 |
| , M.B.B.S | Hospitalist | Omaha, NE | $16.68 | 1 |
| , M.D | Internal Medicine | Omaha, NE | $16.68 | 1 |
| , M.D | Internal Medicine | Omaha, NE | $16.68 | 1 |
| , M.D | Internal Medicine | Omaha, NE | $16.68 | 1 |
| , M.D | Pulmonary Disease | Palmetto Bay, FL | $16.52 | 1 |
| , M.D | Internal Medicine | Johnstown, PA | $16.21 | 1 |
| , M.D | Internal Medicine | Findlay, OH | $16.21 | 1 |
| , M.D | Family Medicine | Johnstown, PA | $16.21 | 1 |
| , MD | Internal Medicine | Johnstown, PA | $16.21 | 1 |
| , M.D | Infectious Disease | Decatur, GA | $16.04 | 1 |
| , M.D | Internal Medicine | Atlanta, GA | $16.04 | 1 |
| , M.D | Infectious Disease | Decatur, GA | $16.04 | 1 |
| , MD | Infectious Disease | Hoboken, NJ | $16.00 | 1 |
| , MD | Internal Medicine | Sylva, NC | $15.98 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $361,106
Product Information
- Type Drug
- Total Payments $361,106
- Total Doctors 346
- Transactions 639
About CUBICIN RF
CUBICIN RF is a drug associated with $361,106 in payments to 346 healthcare providers, recorded across 639 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $78.49 was paid across 5 transactions to 2 doctors.
The most common payment nature for CUBICIN RF is "Unspecified" ($350,956, 97.2% of total).
CUBICIN RF is associated with 5 research studies, including "A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms." ($245,118).